Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (31,038,712)	$ (18,567,234)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation	3,548,368	2,187,149
Depreciation and amortization	111,453
Changes in operating assets and liabilities:
Receivable due from collaboration agreement	(1,628,703)
Research and development tax incentive receivable	(997,802)
Prepaid assets and other current assets	(203,363)	(1,122,495)
Accounts payable	209,193	862,676
Accrued compensation	416,910
Deferred revenue	25,685	24,315
Net cash used in operating activities	(29,556,971)	(16,615,589)
Cash flows from investing activities:
Purchases of property and equipment	(868,505)	(1,102,808)
Net cash used in investing activities	(868,505)	(1,102,808)
Cash flows from financing activities:
Net proceeds from issuance of common stock	28,015,019	24,280,283
Proceeds from issuance of common stock for stock option exercises	689,752	714,382
Proceeds from issuance of common stock for warrant exercises	180,213
Net cash provided by financing activities	28,884,984	24,994,665
Effect of exchange rate changes on cash and cash equivalents	34,359	(70,399)
Net change in cash and cash equivalents	(1,506,133)	7,205,869
Cash and cash equivalents at beginning of year	35,300,805	28,094,936
Cash and cash equivalents at end of year	33,794,672	35,300,805
Supplemental disclosure of non-cash investing and financing activities:
Cashless exercise of warrants	416	530
Issuance of common stock for accrued research and development expense		$ 1,132,013